Company Profile

NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.

Contact Information

Investor Relations
LifeSci Advisors, LLC
Dan Ferry
1 International Place
14th Floor
Boston, MA 02110
T: 617-430-7576

Company Contact
NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219
T: 412-763-3350